RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 PatientsPRNewsWire • 09/14/21
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African ApprovalPRNewsWire • 09/13/21
RedHill Biopharma notes study demonstrates opaganib's efficacy in significantly decreasing renal fibrosisProactive Investors • 09/08/21
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney FibrosisPRNewsWire • 09/07/21
RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare ConferencesPRNewsWire • 09/02/21
RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/26/21
RedHill Biopharma reports second quarter 2021 results, showing record quarterly revenuesProactive Investors • 08/26/21
RedHill Biopharma's Oral COVID-19 Candidate Shows Preclinical Action Against Delta VariantBenzinga • 08/26/21
RedHill Biopharma demonstrates strong inhibition by opaganib of the coronavirus (COVID-19) Delta variantProactive Investors • 08/26/21
RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational HighlightsPRNewsWire • 08/26/21
RedHill Biopharma Ltd Announces RedHill's Opaganib Strong Delta Variant InhibitionAccesswire • 08/26/21
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta VariantPRNewsWire • 08/26/21